Skip to search formSkip to main contentSkip to account menu

danusertib

Known as: Benzamide, 4-(4-methyl-1-piperazinyl)-N-(1,4,5,6-tetrahydro-5-((2R)- methoxyphenylacetyl)pyrrolo(3,4-c)pyrazol-3-yl)- 
A small-molecule 3-aminopyrazole derivative with potential antineoplastic activity. Danusertib binds to and inhibits the Aurora kinases, which may… 
National Institutes of Health

Related topics

Related topics

4 relations
Aurora Kinase A

Broader (2)

BenzamidesPyrazoles

Narrower (1)

PHA 739358

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Wirkung des Aurorakinaseinhibitors Danusertib (PHA-739358) auf nichtseminomatöse Keimzelltumorlinien
Cisplatin gilt als Therapiestandard bei der Behandlung von Keimzelltumoren. Die erreichten signifikanten Heilungsraten von uber… 
2012
2012
New Kinase Inhibitors for the Treatment of Chronic Hematological Neoplasms-Editorial
Protein kinases (PKs) and lipid kinases (LKs) are good targets for signal transduction therapy, as these enzymes are involved in… 
2012
2012
Neuroendocrine Tumors in an Orthotopic Xenograft Model Growth of Liver Metastases from Gastroenteropancreatic Targeting Aurora Kinases with Danusertib (PHA-739358) Inhibits
Purpose: Aurora kinases play a crucial role in cell-cycle control. Uncontrolled expression of aurora kinases causes aneuploidy… 
2012
2012
Developing Drugs for Leukemia’s
At present, available therapies are only partially effective in patients with leukemia and the vast majority of patients cannot… 
2011
2011
Kinases A and B Vulnerability of Ewing ' s Sarcoma to Combined Inhibition of Aurora An Integrated Chemical Biology Approach Identifies Specific
Ewing’s sarcoma is a pediatric cancer of the bone that is characterized by the expression of the chimeric transcription factor… 
2010
2010
Phase II study of danusertib (D) in advanced/metastatic colorectal and pancreatic cancers (CRC, PC).
e13558 Background: D is a pan-aurora kinases inhibitor also active against other kinases with oncogenic potential, such as TRKA… 
2010
2010
Phase I study of danusertib (D) in combination with bevacizumab (B) in solid tumors.
3066 Background: D is a small molecule that inhibits Aurora Kinases, proteins regulating mitosis and overexpressed in many tumors… 
2010
2010
Phase II study of danusertib (D) in advanced/metastatic breast and ovarian cancers (BC, OC).
5014 Background: D is a small molecule that inhibits a urora kinases, proteins regulating mitosis implicated in tumorigenesis and… 
2009
2009
Resistance to Danusertib (formerly PHA-739358) in BCR-ABL-Positive Cells Is Mediated by Upregulation of the Drug Transporter Abcg2 and Can Be Suppressed in Vitro by Combination Treatment with…
Abstract 1724 Poster Board I-750 The success of imatinib (IM, formerly STI571, Gleevec ® ) in the treatment of chronic myeloid… 
2009
2009
Administered as a 24-Hour Infusion with and without Granulocyte Colony-Stimulating Factor in a 14-Day Cycle in Patients with Advanced Solid Tumors
Purpose: This study was conducted to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of the i.v. pan… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)